150 related articles for article (PubMed ID: 17194352)
21. [The condition of the cardiovascular prevention in Spain].
Royo-Bordonada MÁ; Lobos JM; Brotons C; Villar F; de Pablo C; Armario P; Cortés O; Gil Nuñez A; Lizcano A; de Santiago A; Sans S;
Med Clin (Barc); 2014 Jan; 142(1):7-14. PubMed ID: 23433666
[TBL] [Abstract][Full Text] [Related]
22. The REGICOR-calibrated function provides a better classification of high-risk patients on statin treatment in the Spanish population than the Framingham or SCORE classifications.
Baena-Díez JM; Grau M; Sánchez-Pérez R; Altes-Vaques E; Salas-Gaetjens LH; Hernández-Ibáñez MR
Rev Esp Cardiol; 2009 Oct; 62(10):1134-40. PubMed ID: 19793519
[TBL] [Abstract][Full Text] [Related]
23. [Estimating cardiovascular risk in Spain using different algorithms].
Comín E; Solanas P; Cabezas C; Subirana I; Ramos R; Gené-Badía J; Cordón F; Grau M; Cabré-Vila JJ; Marrugat J
Rev Esp Cardiol; 2007 Jul; 60(7):693-702. PubMed ID: 17663853
[TBL] [Abstract][Full Text] [Related]
24. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Disease Management Programs for Cardiovascular Risk and COPD in The Netherlands.
Tsiachristas A; Burgers L; Rutten-van Mölken MP
Value Health; 2015 Dec; 18(8):977-86. PubMed ID: 26686781
[TBL] [Abstract][Full Text] [Related]
26. [Validation of 3 equations of coronary risk in diabetic population of a primary care center].
Cañón-Barroso L; Cruces-Muro E; Fernández-Ochoa G; Nieto-Hernández T; García-Vellido A; Buitrago F
Med Clin (Barc); 2006 Apr; 126(13):485-90. PubMed ID: 16624226
[TBL] [Abstract][Full Text] [Related]
27. [Influence of compliance on the incidence of cardiovascular events and health costs when using single-pill fixed-dose combinations for the treatment of hypertension].
Sicras Mainar A; Galera Llorca J; Muñoz Ortí G; Navarro Artieda R
Med Clin (Barc); 2011 Feb; 136(5):183-91. PubMed ID: 21106209
[TBL] [Abstract][Full Text] [Related]
28. Hypolipidemic drugs in elderly subjects: Indications and limits.
Gazzola K; Vigna GB
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
[TBL] [Abstract][Full Text] [Related]
29. Consequences of using different methods to assess cardiovascular risk in primary care.
Fornasini M; Brotons C; Sellarès J; Martinez M; Galán ML; Sáenz I; da Pena JM
Fam Pract; 2006 Feb; 23(1):28-33. PubMed ID: 16243952
[TBL] [Abstract][Full Text] [Related]
30. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study.
Van Ganse E; Souchet T; Laforest L; Moulin P; Bertrand M; Le Jeunne P; Chretin S; Yin D; Alemao E; de Pouvourville G
Atherosclerosis; 2006 Mar; 185(1):58-64. PubMed ID: 16038912
[TBL] [Abstract][Full Text] [Related]
31. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
32. [ESC/EAS Guidelines for the management of dyslipidaemias].
Reiner Ž; Catapano AL; De Backer G; Graham I; Taskinen MR; Wiklund O; Agewall S; Alegría E; Chapman MJ; Durrington P; Erdine S; Halcox J; Hobbs RH; Kjekshus JK; Perrone Filardi P; Riccardi G; Storey RF; David W;
Rev Esp Cardiol; 2011 Dec; 64(12):1168.e1-1168.e60. PubMed ID: 22115524
[No Abstract] [Full Text] [Related]
33. Is fenofibrate a cost-saving treatment for middle-aged individuals with type 2 diabetes? A South African private-sector perspective.
Wessels F
Cardiovasc J Afr; 2010; 21(1):43-6. PubMed ID: 20224845
[TBL] [Abstract][Full Text] [Related]
34. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting.
Dragomir A; Côté R; White M; Lalonde L; Blais L; Bérard A; Perreault S
Value Health; 2010; 13(1):87-94. PubMed ID: 19695008
[TBL] [Abstract][Full Text] [Related]
35. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of population coronary heart disease risk estimated by the Framingham original and REGICOR calibrated functions].
Ramos R; Solanas P; Cordón F; Rohlfs I; Elosua R; Sala J; Masiá R; Faixedas MT; Marrugat J
Med Clin (Barc); 2003 Oct; 121(14):521-6. PubMed ID: 14599406
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.
Laforest L; Souchet T; Moulin P; Ritleng C; Desamericq G; Le Jeunne P; Schwalm MS; Van Ganse E
Arch Cardiovasc Dis; 2009 Jan; 102(1):43-50. PubMed ID: 19233108
[TBL] [Abstract][Full Text] [Related]
38. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
39. Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS).
Steinhagen-Thiessen E; Bramlage P; Lösch C; Hauner H; Schunkert H; Vogt A; Wasem J; Jöckel KH; Moebus S
Cardiovasc Diabetol; 2008 Oct; 7():31. PubMed ID: 18922160
[TBL] [Abstract][Full Text] [Related]
40. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
Grover SA; Ho V; Lavoie F; Coupal L; Zowall H; Pilote L
Arch Intern Med; 2003 Feb; 163(3):333-9. PubMed ID: 12578514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
